These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 30117378)

  • 1. Performance of tumor testing for Lynch syndrome identification in patients with colorectal cancer: A retrospective single-center study.
    Signoroni S; Tibiletti MG; Ricci MT; Milione M; Perrone F; Pensotti V; Chiaravalli AM; Carnevali I; Morabito A; Bertario L; Vitellaro M
    Tumori; 2019 Feb; 105(1):76-83. PubMed ID: 30117378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Colorectal and Endometrial Microsatellite Instability Tumor Analysis and Premm
    Mannucci A; Furniss CS; Ukaegbu C; Horiguchi M; Fehlmann T; Uno H; Yurgelun MB; Syngal S
    J Clin Oncol; 2020 Dec; 38(34):4086-4094. PubMed ID: 32997573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation.
    Snowsill T; Coelho H; Huxley N; Jones-Hughes T; Briscoe S; Frayling IM; Hyde C
    Health Technol Assess; 2017 Sep; 21(51):1-238. PubMed ID: 28895526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer.
    Hampel H; Pearlman R; Beightol M; Zhao W; Jones D; Frankel WL; Goodfellow PJ; Yilmaz A; Miller K; Bacher J; Jacobson A; Paskett E; Shields PG; Goldberg RM; de la Chapelle A; Shirts BH; Pritchard CC;
    JAMA Oncol; 2018 Jun; 4(6):806-813. PubMed ID: 29596542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The proportion of endometrial tumours associated with Lynch syndrome (PETALS): A prospective cross-sectional study.
    Ryan NAJ; McMahon R; Tobi S; Snowsill T; Esquibel S; Wallace AJ; Bunstone S; Bowers N; Mosneag IE; Kitson SJ; O'Flynn H; Ramchander NC; Sivalingam VN; Frayling IM; Bolton J; McVey RJ; Evans DG; Crosbie EJ
    PLoS Med; 2020 Sep; 17(9):e1003263. PubMed ID: 32941469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathologic Comparison of Lynch Syndrome-associated and "Lynch-like" Endometrial Carcinomas Identified on Universal Screening Using Mismatch Repair Protein Immunohistochemistry.
    Mills AM; Sloan EA; Thomas M; Modesitt SC; Stoler MH; Atkins KA; Moskaluk CA
    Am J Surg Pathol; 2016 Feb; 40(2):155-65. PubMed ID: 26523542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of screening strategies for Lynch syndrome in patients with newly diagnosed endometrial cancer: a prospective cohort study in China.
    Chao X; Li L; Wu M; Ma S; Tan X; Zhong S; Bi Y; Lang J
    Cancer Commun (Lond); 2019 Jul; 39(1):42. PubMed ID: 31307542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of HNPCC by molecular analysis of colorectal and endometrial tumors.
    Vasen HF; Hendriks Y; de Jong AE; van Puijenbroek M; Tops C; Bröcker-Vriends AH; Wijnen JT; Morreau H
    Dis Markers; 2004; 20(4-5):207-13. PubMed ID: 15528786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility of screening for Lynch syndrome among patients with colorectal cancer.
    Hampel H; Frankel WL; Martin E; Arnold M; Khanduja K; Kuebler P; Clendenning M; Sotamaa K; Prior T; Westman JA; Panescu J; Fix D; Lockman J; LaJeunesse J; Comeras I; de la Chapelle A
    J Clin Oncol; 2008 Dec; 26(35):5783-8. PubMed ID: 18809606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor testing to identify lynch syndrome in two Australian colorectal cancer cohorts.
    Buchanan DD; Clendenning M; Rosty C; Eriksen SV; Walsh MD; Walters RJ; Thibodeau SN; Stewart J; Preston S; Win AK; Flander L; Ouakrim DA; Macrae FA; Boussioutas A; Winship IM; Giles GG; Hopper JL; Southey MC; English D; Jenkins MA
    J Gastroenterol Hepatol; 2017 Feb; 32(2):427-438. PubMed ID: 27273229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular analysis of Iranian colorectal cancer patients at risk for Lynch syndrome: a new molecular, clinicopathological feature.
    Zeinalian M; Emami MH; Salehi R; Naimi A; Kazemi M; Hashemzadeh-Chaleshtori M
    J Gastrointest Cancer; 2015 Jun; 46(2):118-25. PubMed ID: 25722176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome.
    Rabban JT; Calkins SM; Karnezis AN; Grenert JP; Blanco A; Crawford B; Chen LM
    Am J Surg Pathol; 2014 Jun; 38(6):793-800. PubMed ID: 24503759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PREMM5 distinguishes sporadic from Lynch syndrome-associated MMR-deficient/MSI-high colorectal cancer.
    Sandoval RL; Horiguchi M; Ukaegbu C; Furniss CS; Uno H; Syngal S; Yurgelun MB
    Fam Cancer; 2023 Oct; 22(4):459-465. PubMed ID: 37572151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the clinical prediction model PREMM(1,2,6) and molecular testing for the systematic identification of Lynch syndrome in colorectal cancer.
    Kastrinos F; Steyerberg EW; Balmaña J; Mercado R; Gallinger S; Haile R; Casey G; Hopper JL; LeMarchand L; Lindor NM; Newcomb PA; Thibodeau SN; Syngal S;
    Gut; 2013 Feb; 62(2):272-9. PubMed ID: 22345660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF mutation analysis is a valid tool to implement in Lynch syndrome diagnosis in patients classified according to the Bethesda guidelines.
    Molinari F; Signoroni S; Lampis A; Bertan C; Perrone F; Sala P; Mondini P; Crippa S; Bertario L; Frattini M
    Tumori; 2014; 100(3):315-20. PubMed ID: 25076244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early-onset colorectal cancer patients without family history are "at very low risk" for lynch syndrome.
    Stigliano V; Sanchez-Mete L; Martayan A; Diodoro M; Casini B; Sperduti I; Anti M
    J Exp Clin Cancer Res; 2014 Jan; 33(1):1. PubMed ID: 24383517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer.
    Pérez-Carbonell L; Ruiz-Ponte C; Guarinos C; Alenda C; Payá A; Brea A; Egoavil CM; Castillejo A; Barberá VM; Bessa X; Xicola RM; Rodríguez-Soler M; Sánchez-Fortún C; Acame N; Castellví-Bel S; Piñol V; Balaguer F; Bujanda L; De-Castro ML; Llor X; Andreu M; Carracedo A; Soto JL; Castells A; Jover R
    Gut; 2012 Jun; 61(6):865-72. PubMed ID: 21868491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lynch syndrome pre-screening and comprehensive characterization in a multi-center large cohort of Chinese patients with colorectal cancer.
    Li Y; Fan L; Zheng J; Nie X; Sun Y; Feng Q; Lian S; Bai W; Cai W; Yang Y; Su B; Xi Y; Lin D
    Cancer Biol Med; 2022 Jun; 19(8):1235-48. PubMed ID: 35638907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The proportion of endometrial cancers associated with Lynch syndrome: a systematic review of the literature and meta-analysis.
    Ryan NAJ; Glaire MA; Blake D; Cabrera-Dandy M; Evans DG; Crosbie EJ
    Genet Med; 2019 Oct; 21(10):2167-2180. PubMed ID: 31086306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and Clinical Implications of Mismatch Repair-Proficient Colorectal Cancer in Patients With Lynch Syndrome.
    Ranganathan M; Sacca RE; Trottier M; Maio A; Kemel Y; Salo-Mullen E; Catchings A; Kane S; Wang C; Ravichandran V; Ptashkin R; Mehta N; Garcia-Aguilar J; Weiser MR; Donoghue MTA; Berger MF; Mandelker D; Walsh MF; Carlo M; Liu YL; Cercek A; Yaeger R; Saltz L; Segal NH; Mendelsohn RB; Markowitz AJ; Offit K; Shia J; Stadler ZK; Latham A
    JCO Precis Oncol; 2023 May; 7():e2200675. PubMed ID: 37262391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.